Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Clinical Trial of Tarlatamab as Maintenance Treatment After Sequential Chemo-radiotherapy for Limited Stage SCLC Patients Not Eligible for Concurrent Chemo-radiotherapy

NCT07242547 is registered in ClinicalTrials.gov with Fundación GECP as lead sponsor.

NCT NCT07242547
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07242547 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Clinical Trial of Tarlatamab as Maintenance Treatment After Sequential Chemo-radiotherapy for Limited Stage SCLC Patients Not Eligible for Concurrent Chemo-radiotherapy
Lead sponsor
Fundación GECP
Phase
Phase 2
Overall status
Recruiting
Start date
May 20, 2026
Completion date
June 1, 2030
Enrollment
37 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, small cell lung, limited-stage small-cell lung cancer, respiratory tract neoplasms, thoracic neoplasms